GSAR Journal of Agriculture and Veterinary Sciences
ISSN: 3048-9075 (Online)
Abbreviated key title: Glob.J. Agri.Vet.Sci.
Frequency: Monthly
Published By GSAR Publishers
Journal Homepage Link- https://gsarpublishers.com/journal-gjavs-home/

RNA Interference (RNAi) for FMD Treatment: A Biotechnological strategy

By

Mareena Kanwal[1], Muhammad Sufyan[2*], Syed Muhammad Salman Saeed[3], Imtiaz Hussain[4],Mahrukh Haseeb[5], Muhammad Uzair[6], Sidra Siddique[7], Laiba Arshad[8], Ahmed Raza[9], Muhammad Arslan Arshad[9]

[1]Department of Biotechnology, International Islamic University, Islamabad
[2]Institute of Microbiology, University of Agriculture Faisalabad
[3]Department of Biotechnology, Qarshi University Lahore
[4]Department of Biotechnology, University of Agriculture Faisalabad
[5]Department of Biotechnology, Mirpur University of Science and Technology
[6]Department of Biotechnology, Virtual University of Pakistan
[7]Department of Microbiology , University of Jhang
[8]Department of Zoology, Riphah International University, Faisalabad
[9]Faculty of Veterinary and Animal Sciences Gomal University Dera Ismail Khan

Article History

Received: 15/06/2025
Accepted: 23/06/2025
Published: 25/06/2025

Vol – 2 Issue –6

PP: -116-123

DOI:10.5281/zenodo.15737927

Abstract

Foot-and-Mouth Disease (FMD) is a serious, extremely infectious virus that threatens livestock and food security and has an effect on agricultural economy and animal health worldwide. The shortcomings of current management measures, such as immunization, emphasize the need for other approaches. Because it targets viral gene expression directly, RNA interference (RNAi) has become a possible biotechnological therapy for FMD. Double-stranded RNA is naturally broken down into tiny RNAs (such as siRNA/shRNA) that direct the RNA-induced silencing complex (RISC) to complementary viral messenger RNA (mRNA), causing translational repression or mRNA destruction. Viral protein synthesis and replication are inhibited by this post-transcriptional silencing. Important FMDV genes, such VP1 (which is necessary for cell entrance) and 3D Polymerase (which is involved in replication), are good targets for RNA interference. Research has shown that VP1 significantly reduces viral replication both in vitro and in vivo (by 80–90%). To address issues including RNA degradation and inadequate cellular absorption, effective delivery methods are being investigated, such as lipid-based nanoparticles and adenovirus vectors. Notwithstanding encouraging outcomes, there are still issues, such as the delayed start of silence, the genetic diversity of the virus that can result in escape mutants, ineffective delivery, and possible off-target consequences. Finding conserved targets to treat variability is being aided by computational techniques. In the future, RNAi design will be improved (e.g., multiplex targeting), delivery methods will be improved, RNAi will be integrated with vaccination tactics, and manufacturing and regulatory obstacles will be addressed. RNAi holds substantial potential to revolutionize FMD management, but continued research and optimization are essential.

Keywords: *RNA Interference (RNAi), Foot-and-Mouth Disease (FMD), Foot-and-mouth disease virus (FMDV), Gene Silencing, Viral Replication, siRNA / shRNA, Delivery Systems, VP1*

Introduction

A serious threat to both agricultural economy and animal health worldwide is foot-and-mouth disease (FMD). An overview of FMD will be given in this introduction, along with a discussion of its substantial effects on agriculture and the economy [1]. The limits of the existing management strategies will also be covered, and RNA interference (RNAi)

*Corresponding Author: **Muhammad Sufyan**

will be presented as a viable alternative biotechnological treatment option. Animals with cloven hooves are susceptible to the extremely crippling viral illness known as foot-and-mouth disease. It is regarded as a serious animal health issue and one of the most dreaded viral illnesses of agricultural animals [2]. It is an acute, febrifacient, and extremely infectious disease. Domesticated ruminants, pigs, camels, cattle, sheep, goats, and over 70 species of wild animals are among the susceptible animals. The Foot-and-Mouth Disease Virus (FMDV), the prototype member of the Aphthovirus genus within the Picornaviridae family, is the cause of the disease [3]. The icosahedral capsid of the non-enveloped FMDV particle contains a single-stranded, positive-sense RNA genome. The genome has between 7000 and 8500 base pairs [4]. With seven serotypes (A, O, C, Asia1, SAT1, SAT2, and SAT3) and other subtypes, FMDV has a very diverse antigenome. One of the virus's main traits is its great genetic diversity. Fever, lameness, vesicles on the tongue, lips, and feet, a reduction in milk output, and a decline in animal vigor and fertility are some of the clinical symptoms that define FMD [5]. One of the most significant new viral illnesses affecting animals with cloven hooves is known to be FMD. The World Organization for Animal Health (OIE) keeps an eye on it since it is a disease that may spread quickly in vulnerable animals. The illness is seen as a serious threat to the worldwide livestock sector and results in large financial losses [6]. Animal production and health are seriously threatened by it, especially in underdeveloped nations where financial losses are a big worry. In addition, it poses a worldwide risk to food security and significantly harms the cattle sector and its farmers financially [7]. According to estimates, FMD costs the world economy about $10 billion a year. Public awareness has grown considerably as a result of outbreaks in nations free of FMD. For instance, the 2001 epidemic in the UK had severe economic repercussions, affecting over 2000 farms and leading to the death of several million animals [8]. It has also been noted that terrorist groups or rogue governments may use the FMD agent to target the $100 billion-a-year US cattle business. While disease management methods and the high expense of control and preventive initiatives are indirect repercussions of an FMD outbreak, significant losses to agricultural productivity and disruption of local economy are direct effects [9]. One of the most important ways to prevent and control FMD infection is by vaccination. In many nations or areas, vaccinations have been successful in containing and eliminating the virus. Animal mobility restrictions, immunization with chemically-inactivated viruses, and the killing of diseased and afflicted animals are common methods of disease management. However, the effectiveness of traditional treatments especially vaccination in stopping epidemics is limited [10]. RNA interference, or RNAi, has become a viable alternative technique to regulate virus reproduction and viral transmission due to the shortcomings of traditional methods, especially the difficulties caused by the virus's unpredictability and the requirement for quick interventions [11]. In eukaryotic cells, RNA interference (RNAi) is an evolutionarily conserved process that controls post-transcriptional silencing of sequence-specific genes. Double-stranded RNA (dsRNA) initiates it, and the RNA-induced silencing complex (RISC) causes complementary messenger RNA (mRNA) to degrade. It is assumed that RNA interference (RNAi) protects against viruses [12]. The traditional methods for controlling significant animal diseases may be enhanced and supplemented by RNA interference (RNAi) technology because of its great specificity and speed. Another strategy for limiting FMDV transmission has been shown to be the application of RNAi-based techniques [13]. Small RNA molecules, including short interfering RNAs (siRNAs), microRNAs (miRNAs), and short hairpin RNAs (shRNAs), have been investigated in a number of studies for their ability to prevent FMDV replication in vitro and in vivo. This biotechnological approach, with its direct effect on the FMDV genome and potential for targeting conserved viral regions, offers a new avenue for developing effective inhibitors and therapies against foot-and-mouth disease [14].

Mechanism of RNA Interference in FMD Treatment

A naturally occurring biological phenomenon known as RNA interference occurs when tiny non-coding RNA molecules post-transcriptionally suppress gene expression. This is accomplished either by blocking translation or by breaking down corresponding messenger RNA (mRNA). Designing short hairpin RNAs (shRNAs) and small interfering RNAs (siRNAs) that selectively target important viral genes involved in FMDV replication is the main strategy for the antiviral use of RNA interference (RNAi) in FMD [15]. Double-stranded RNA (dsRNA) is introduced into the cell to start RNA interference. After being absorbed by cells, dsRNA is broken down into tiny RNA pieces that are between 21 and 23 nucleotides long by an enzyme called Dicer. The RNA-induced silencing complex (RISC), which causes gene silencing by directing the complex to complementary viral mRNA sequences and causing their destruction or translational repression, then incorporates these pieces [16].



Figure 1: This figure depicts the molecular pathway of RNA interference triggered in response to viral RNA. It shows the formation of primary (pri-miRNA) and precursor (pre-miRNA) microRNAs in the nucleus, their transport to the cytoplasm, and the interaction of short hairpin RNA (shRNA) and viral single-stranded RNA (ssRNA) with the RNAi

*Corresponding Author: **Muhammad Sufyan**

machinery. The viral RNA serves both as a trigger and target of RNA interference, ultimately reducing viral replication through the silencing of viral genes [17].

Sequence Specificity: RNAi-induced silencing is a very particular technique for silencing viral genes since it relies on the exact base matching between the short RNA and the target Mrna [18].

Regulation of Posttranscription: RNA interference (RNAi) stops the production of viral proteins necessary for virus entry, replication, and assembly by targeting viral mRNAs. Because FMDV genes are conserved across different serotypes, they have been found to be appropriate RNA interference targets in many studies [19].

VP1: A structural protein necessary for viral attachment to host cells is encoded by the VP1 gene. Numerous investigations have shown that siRNA targeting of VP1 reduces viral multiplication by 80–90% in vitro and in vivo [20].

Silencing 3D Polymerase, which is involved in viral genome replication, can prevent the production of viral RNA and hence restrict the spread of the virus. Additional targets that are crucial to the viral life cycle are VP4 and 2B [21]. In cell culture models, it has been demonstrated that the synergistic silencing of many viral genes increases the inhibitory effects on viral replication. Key viral targets for RNA interference in FMD treatment are compiled in the table below:

Viral Target Gene	Function	RNAi Impact
VP1	Structural protein, mediates cell entry	80–90% reduction in viral replication [22].
3D Polymerase	RNA-dependent RNA polymerase	Inhibits viral replication [23].
VP4	Structural protein	Contributes to viral inhibition [24].
2B	Nonstructural protein	Blocks viral replication [25].

Table 1: Key FMDV genes targeted by RNAi-based therapeutics [26].

RNA interference (RNAi) has been shown to drastically limit FMDV replication. When BHK-21 cells are transfected with RNAi constructs, for example, it has been demonstrated that the cells become resistant to FMDV infection when exposed to infectious dosages. Furthermore, the effects of RNA interference are not temporary; they can last for nearly 48 hours after infection, demonstrating the effectiveness of this antiviral strategy [27]. The RNAi machinery lowers the viral burden in infected animals by limiting genomic replication and decreasing viral protein synthesis. The RNAi process in an FMDV-infected cell is depicted schematically in Figure 2, which is shown below.



Figure 2: The flowchart above provides a clear representation of how the RNAi pathway leads to the silencing of viral gene expression, thereby mitigating FMDV replication [28].

RNAi Delivery Systems for FMD Management

For treatment to be effective, RNAi constructs must be delivered into target cells efficiently. The delivery systems need to get past obstacles such endosomal trapping, low cellular uptake, and nuclease destruction. To improve the transport of RNAi molecules, current research has investigated a number of novel viral and non-viral vectors [29]. Using adenovirus vectors is one of the most promising methods for delivering RNA interference. In animal models, adenovirus-mediated RNA interference has been effectively used to target FMDV genes. For instance, it has been demonstrated that recombinant adenovirus type 5 constructs that express shRNAs that target either the structural protein VP1 or the polymerase 3D protect pig cells and dramatically lower FMDV infection in vivo [30]. Pretreatment with these adenoviral vectors decreased the occurrence of clinical signs linked to FMD, such as vesicle development on the foot, in guinea pig and swine models. This technique makes use of adenovirus vectors' high transduction efficiency to guarantee that a significant quantity of RNAi construct enters the target cells [31]. The transport of siRNA has also been extensively studied using lipid-based delivery vehicles, such as lipoplexes. These systems have the ability to shield siRNA molecules from nuclease breakdown and promote endocytosis, which allows for cellular absorption. The escape of siRNA from endosomes is still a significant obstacle, though, since research indicates that fewer than 1% of siRNA makes it to the cytoplasm [32]. Additional methods for enhancing the pharmacokinetics and biodistribution of RNA interference agents are offered by nanoparticles, which include inorganic and polymer-based carriers. Despite these developments, issues like triggering inflammation and cell

*Corresponding Author: **Muhammad Sufyan**

death still require careful adjustment. Commensal bacteria have been investigated recently as a potential delivery system for symbiont-mediated RNA interference [33]. This method delivers RNAi constructs using naturally existing microorganisms, which may improve selectivity and lessen side effects. PEGylation is another chemical modification that has been used to stabilize siRNA molecules. By shielding siRNA from phosphatase and nuclease degradation, these changes increase serum stability and lessen off-target effects [34]. The main delivery methods for RNAi-based FMD treatments, together with their benefits and drawbacks, are compiled in the following table:

Delivery System	Advantages	Limitations
Adenovirus-Mediated Delivery	High transduction efficiency; effective in vivo	Potential immunogenicity; limited payload capacity [35]
Lipid-Based Nanoparticles	Protects siRNA; enhances cellular uptake	Low endosomal escape rates (<1% efficiently released) [36]
Symbiont-Mediated Delivery	Natural and potentially less immunogenic	Limited data in field application; scalability issues [37]
Chemical Modifications (PEGylation)	Improved serum stability; reduced off-target effects	May affect RNAi efficiency; complex formulation [38]

Table 2: Comparison of RNAi Delivery Systems for FMD Therapeutics.

Current Research Insights and Computational Approaches

Our knowledge of RNAi in relation to FMD treatment has greatly increased as a result of recent research. The thorough assessment of RNAi's ability to contain FMD epidemics is aided by insights from both empirical studies and computer analysis. The strong antiviral properties of RNA interference against FMDV are demonstrated by empirical data from many research teams. RNAi constructs that target VP1 have been shown in experiments on BHK-21 cells to reduce FMDV replication by 80–90% [39]. The great specificity and efficacy of RNAi-mediated gene silencing are confirmed by the transfected cells' strong resistance to infectious dosages. Results from in vivo research utilizing guinea pig and swine models have been promising. With notable reductions in viral titers and elevated survival rates in treated animals, adenovirus-based vectors expressing RNAi constructs, for example, produced the best protection rates when given both before and after FMDV infection [40]. These experiments' success offers a solid basis for RNA interference's possible use in cattle. Computational techniques have been used to find conserved target areas within the viral genome because of the great genetic heterogeneity of FMDV [41]. Several host miRNAs that may target FMDV sequences have been identified by computational investigations employing miRNA target prediction techniques. For instance: 12 mature host miRNAs with 284 targets spanning 98 FMDV sequences were found through computational study, indicating that host-derived miRNAs may target viral transcripts to provide additional antiviral effects [42]. Eight probable targetable areas in the FMDV genome have been identified by further study. These regions are very different from the host genome, which makes them perfect candidates for artificial siRNA treatments. Furthermore, the toolset for RNAi intervention in FMD treatment was expanded when 16 simulated nucleotide sequences that had over 90% similarity to mature miRNAs were shown to be prospective RNAi agents against FMDV [43]. By reducing off-target effects on the host's genome and guaranteeing that targets are conserved across different FMDV serotypes, these computational insights aid in the improvement of RNAi molecule design. Optimizing RNAi techniques requires the combination of computational predictions and experimental data [44]. A suggested methodology combines in vitro and in vivo validation investigations with in silico target discovery, as shown in Figure 3.



Figure 3: This flowchart underscores the necessity of iterative testing and optimization to develop clinically relevant RNAi therapeutics for FMD.

Challenges in RNAi Applications for FMD

Even with encouraging developments, a number of obstacles still need to be overcome before RNAi treatment may be widely used in clinical settings for FMD. These problems are complex and span the fields of biology, technology, and regulation. The delay in the beginning of silencing is a notable drawback of RNAi-mediated FMD therapy [45]. According to studies, it takes around 24 to 48 hours for the effects of RNA interference to become noticeable enough to stop the spread of viruses. For fast-moving viral illnesses like FMD, where the virus may spread more quickly than the inhibitory effects can be demonstrated, this time lag might be very significant. High genetic diversity and the establishment of many serotypes are characteristics of FMDV [46]. Because even minor alterations in the target regions might make RNAi

*Corresponding Author: **Muhammad Sufyan**

molecules less effective or useless altogether, this intrinsic unpredictability presents a serious problem for RNAi treatment. By altering the sequences that siRNAs or shRNAs target, the virus may become resistant to RNA interference and select escape forms [47]. Combinatorial strategies that target several conserved areas of the viral genome are required to get beyond these barriers, but also complicate the creation and administration of RNAi constructs. The plasma and tissues contain nucleases that may break down RNA molecules [48]. A significant portion of RNAi molecules are held in the endosomal compartments during cellular absorption, which limits their availability in the cytoplasm, where RISC assembly takes place. Unintentional innate immune system activation can cause inflammation and off-target consequences, which might complicate the overall treatment profile [49].

Effects Off-Target and Cytotoxicity: Despite RNAi's excellent specificity, off-target gene silencing is still a worry. Unintentional gene silencing may result from partial sequence complementarity between the siRNA/shRNA and non-target mRNAs [50]. At larger dosages, the delivery vehicles especially chemical carriers and viral vectors may cause cytotoxic consequences, therefore careful dose optimization and thorough safety evaluation are required.

A number of industrial and regulatory obstacles need to be addressed from a translational standpoint. Robust and repeatable manufacturing procedures are necessary to produce RNAi molecules and their carriers at a scale that satisfies clinical and field demands [51]. Standardized procedures are required to assess the safety, effectiveness, and long-term effects of RNAi-based medicines, as they constitute a novel class of pharmaceuticals and regulatory standards are still developing. The availability of RNAi-based treatments in areas most impacted by FMD, especially in poor nations, may be restricted by high production costs [52].

Future Directions in RNAi-Based FMD Therapies

Notwithstanding the significant obstacles, there are encouraging prospects for further study and clinical use of RNA interference in the treatment of FMD. The goal of ongoing research is to improve delivery methods, combine RNAi with current immunization approaches, and improve RNAi design creating RNA interference molecules that target several conserved areas of FMDV at once in order to reduce the possibility of escape mutants and improve overall antiviral effectiveness [53]. More durable and effective RNAi responses may result from engineering amiRs to resemble the structure and function of endogenous miRNAs. According to recent research, amiRs can specifically silence reporter genes that are coupled to FMDV sequences [54]. Finding the best target sequences within the FMDV genome will continue to require the use of sophisticated bioinformatics techniques and target prediction algorithms. Finding strong RNAi candidates will be made easier with continued integration of computational data and experimental validation [55]. Considerable advancements in delivery technology are necessary to translate RNA interference into clinical practice. Future research should concentrate on creating nanoparticles that effectively escape endosomal compartments while also shielding RNAi molecules from destruction [56]. Biocompatible carriers with improved tissue penetration capabilities might be produced by advances in material science. Adenovirus-based vectors have showed promise, but more changes are needed to improve target selectivity and decrease immunogenicity. Viral vectors and chemical alterations may work in concert to maximize the advantages of each strategy [57]. Investigating commensal bacteria's potential as delivery systems might result in a less immunogenic and more natural way to distribute RNAi creations. Given its potential for use in integrated pest management strategies, this topic merits more research [58]. There is a lot of interest in combination therapy techniques because of the shortcomings of conventional immunization strategies:

Use of Adjuvants: RNAi-based therapies may be useful adjuvants for vaccines, improving the immune system as a whole and directly lowering virus replication [59]. By eradicating the virus and creating a strong immune memory, RNA interference (RNAi) in combination with traditional vaccinations may provide twofold protection [60].

Sequential Therapy: RNAi constructs might be administered as a preventative intervention before or after exposure as part of current vaccination regimens to provide rapid antiviral effects and then long-lasting vaccine-induced immunity [61].

To confirm the safety and effectiveness of RNAi therapies, extensive research in animal models is required. Regulatory agencies will find it easier to assess these innovative treatments if preclinical procedures are standardized [62]. A roadmap for comparable research in veterinary medicine is provided by encouraging outcomes from early-phase clinical trials in other RNAi-based medicines, such as those in cancer [63]. Gaining knowledge from these experiences will hasten the regulatory approval procedure for FMD treatments based on RNA interference. The economic viability of RNAi therapeutics will depend on developments in large-scale synthesis and formulation, especially in areas where FMD is endemic and resources may be few [64].

Conclusion

RNA interference, which targets viral gene expression selectively, offers a revolutionary method of managing foot-and-mouth disease. The combined data from in vitro and in vivo investigations highlights RNAi's strong antiviral properties against important FMDV genes including VP1, 3D, VP4, and 2B. Advances in vector design and computer target prediction provide promising answers despite major obstacles, including the delayed initiation of RNA interference effects, the generation of escape mutants, delivery inefficiencies, and possible off-target effects. Through the integration of siRNA into RISC, RNAi causes gene silence, which results in the destruction of viral mRNA and the prevention of viral replication. Viral replication has been significantly reduced in both cell culture and animal models as a result of RNA

*Corresponding Author: **Muhammad Sufyan**

interference's successful targeting of conserved regions within FMDV, including VP1 and 3D. While lipid-based nanoparticles and symbiont-mediated methods are still being researched, adenovirus-mediated delivery systems have shown efficacy in attaining effective transduction. To ensure both effectiveness and specificity in RNAi design, conserved RNAi target sites must be identified using bioinformatics and computational modeling. Temporal delays, viral genetic diversity, transport hurdles, and possible off-target effects all reduce the effectiveness of RNA interference and call for more testing and validation. Translating RNAi research into practical applications requires a focus on multiplex RNAi techniques, improved delivery systems, integration with traditional immunization, and shortened regulatory routes. To sum up, RNA interference has a lot of potential as a cutting-edge, focused, and successful treatment approach for managing FMD. Overcoming current obstacles requires sustained work to enhance delivery methods, optimize RNAi design, and combine computational insights with experimental validations. RNAi-based treatments have the potential to transform FMD management with more study and clinical development, ultimately lowering financial losses and enhancing cattle health globally.

References

1. Arzt J., Baxt B., Grubman M., Jackson T., Juleff N., Rhyan J., Rieder E., Waters R. & Rodriguez L. (2011). The Pathogenesis of FootμandμMouth Disease II: Viral Pathways in Swine, Small Ruminants, and Wildlife; Myotropism, Chronic Syndromes, and Molecular Virus–Host Interactions. Trans boundary and emerging diseases, 58, 305-326.
2. Abrams, C. C., A. M. King, and G. J. Belsham. 1995. Assembly of foot and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J. Gen. Virol. 76:3089–3098.
3. Ali, M. Z., Dewan, D., Khan, M. M. R., & Meher, M. M. (2024). Prevalence, Genetic Characteristics and Economic Losses of Foot-and Mouth Disease Virus (FMD) in Global and Bangladesh Context: A Review. Ukrainian Journal of Veterinary and Agricultural Sciences, 7(2), 8–19.
4. Aidaros, H. A. (2002). Regional status and approaches to control ling and eradicating foot and mouth disease in the Middle East and North Africa. The Scientific and Technical Review, 21(3), 451–458.
5. Alexandersen, S., Zhang, Z. & Donaldson, A. I. (2002). Aspects of the persistence of footand-mouth disease virus in animals—the carrier problem. Microbes and Infection, 4(10), 1099–1110.
6. MT, RHDS, AP, MADS (2023). Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70 MF59). Arch. Razi Inst., 78(3):907-913
7. Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, Ugwuja EI, Aja PM (2023). Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci. Rep., 13(1):13398, https://doi.org/10.1038/s41598-023-40160-2
8. Aida V, Pliasas VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS (2021). Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines. Front. vet. sci., 8, https://doi.org/10.3389/fvets.2021.654289
9. Aidinis V, Chandras C, Manoloukos M, Thanassopoulou A, Kranidioti K, Armaka M, Douni E, Kontoyiannis DL, Zouberakis M, Kollias G (2007). MUGEN mouse database; Animal models of human immunological diseases. Nucleic acids res., 36(Database): D1048-D1054, https://doi.org/10.1093/nar/gkm838
10. Abbas A, Kumar L, Rehman S, Mathan, Yousaf A (2021) Prevalence of Gastrointestinal Parasites in Buffalo and Cow Calves in Rural Areas of Rawalpindi, Pakistan. Biomed J Sci & Tech Res 40 (2): 32159-32165. DOI: http://dx.doi.org/10.26717/BJSTR.2021.40.006437
11. Abbas T., et al. “Some challenges to progressive control of foot and mouth disease in Pakistan - findings of a pilot survey”. Transboundary and Emerging Diseases (2012).
12. Ayelet G., et al. “Study on the epidemiology of foot and mouth disease in Ethiopia”. Revue scientifique et technique 31 (2012): 789-798.
13. Collins JE, Benfield DA, Christianson WT, et al. Isolation of swine infertility and respiratory syndrome virus (isolate ATCC VR2332) in North America and experimental reproduction of the disease in gnotobiotic pigs. J Vet Diagn Invest 1992;4: 11726.
14. Hu J, Zhang C. Porcine reproductive and respiratory syndrome virus vaccines: current status and strategies to a universal vac cine. Transbound Emerg Dis 2014;61:10920.
15. Alexandersen S, Zhang Z, Donaldson AI, Garland AJ. The pathogenesis and diagnosis of footandmouth disease. J Comp Pathol 2003;129:136.
16. Adachi T, Kawakami E, Ishimaru N, Ochiya T, Hayashi Y, Ohuchi H, Tanihara M, Tanaka E, Noji S (2010) Delivery of small interfering RNA with a synthetic collagen poly(Pro-Hyp-Gly) for gene silencing in vitro andinvivo.Development,Growth&Differentiation52, 693–699. doi:10.1111/j.1440-169X.2010.01206.x
17. Anderson JF, Magnarelli LA (2008) Biology of ticks. Infectious Disease Clinics of North America 22, 195–215. doi:10.1016/j.idc.2007.12.006
18. Australian Government (2014) Australia New Zealandfood standards code Standard 1.5.2– Food

*Corresponding Author: **Muhammad Sufyan**

produced using gene technology. Available at www.comlaw.gov.au/Details/F2014C01175 [Verified 3 August 2015]
19. Committee for Advanced Therapies (CAT), "Reflection paper on classification of advanced therapy medicinal products," EMA/CAT/600280/2010, 2012.
20. S.A.Rosenberg,P.Aebersold,K.Cornettaetal.,"Genetr ans fer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction," New England Journal of Medicine, vol. 323, no. 9, pp. 570–578, 1990.
21. Orsel, K., Bouma, A., Dekker, A., Stegeman, J. A. & De Jong, M. C. M. Foot and mouth disease virus transmission during the incubation period of the disease in piglets, lambs, calves, and dairy cows. Prev. Vet. Med. 88(2), 158–163 (2009).
22. Tan, E. L. & Hann Chu, J. J. RNA interference (RNAi)—An antiviral strategy for enteroviruses. J. Antivir. Antiretrovir. https://doi. org/10.4172/jaa.S9-002 (2011).
23. Gismondi, M. I., Ortiz, X. P., Currá, A. P., Asurmendi, S. & Taboga, O. Artificial microRNAs as antiviral strategy to FMDV: Struc tural implications of target selection. J. Virol. Methods 199, 1–10 (2014).
24. Wen, B. P., Dai, H. J., Yang, Y. H., Zhuang, Y. & Sheng, R. MicroRNA-23b inhibits enterovirus 71 replication through downregula tion of EV71 VPl protein. Intervirology 56, 195–200 (2013).
25. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342-347.
26. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest. 2007;117:1456-1465.
27. One of three successfully treated CGD patients in a Swiss German gene therapy trial died due to his underlying disease: A position statement from the European Society of Gene Therapy (ESGT). J Gene Med. 2006;8:1435.
28. Ao, D., Guo, H. C., Sun, S. Q., Sun, D. H., Fung, T. S., Wei, Y. Q., et al. (2015). Viroporin activity of the foot-and-mouth disease virus non-structural 2B protein. PLoS ONE 10:e0125828. doi: 10.1371/journal.pone.0125828
29. Barral, P. M., Sarkar, D., Fisher, P. B., and Racaniello, V. R. (2009). RIG-I is cleaved during picornavirus infection. Virology 391, 171–176. doi: 10.1016/j.virol.2009.06.045
30. Berke, I. C., Li, Y., and Modis, Y. (2013). Structural basis of innate immune recognition of viral RNA. Cell. Microbiol. 15, 386–394. doi: 10.1111/cmi.12061
31. Knight-Jones TJ, Rushton J (2013) The economic impactsof foot and mouthdisease—what are they, howbigaretheyandwheredotheyoccur?PrevVetMed 112:161–173.doi:10.1016/j.prevetmed. 2013.07.013 PMID: 23958457
32. Acharya R, Fry E, Stuart D, FoxG, Rowlands D,BrownF(1989)Thethree-dimensional structureof foot-and-mouth disease virus at 2.9 A resolution. Nature 337: 709–716. PMID: 2537470
33. Jackson T, Sheppard D,DenyerM,BlakemoreW,KingAM(2000)Theepithe lialintegrinalphavbeta6 is a receptor for foot-and-mouth disease virus. J Virol 74: 4949–4956. PMID: 10799568
34. MonaghanP,GoldS,SimpsonJ,ZhangZ,WeinrebPH, VioletteSMetal.(2005)Thealpha(v)beta6 integrin receptor for Foot-and-mouth disease virus is expressed constitutively on the epithelial cells tar geted in cattle. J Gen Virol 86: 2769–2780. PMID: 16186231
35. Rodriguez LL, Grubman MJ(2009)Footandmouthdiseasevirusvaccines. Vaccine 27Suppl4: D90 94. doi: 10.1016/j.vaccine.2009.08.039 PMID: 19837296
36. Brooksby JB (1982) Portraits of viruses: foot-and-mouth disease virus. Intervirology 18: 1–23.
37. Ameres, S. L., Martinez, J., and Schroeder, R. (2007). Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130, 101–112. doi: 10.1016/j.cell.2007.04.037
38. Aoki, K., Moriguchi, H., Yoshioka, T., Okawa, K., and Tabara, H. (2007). In vitro analyses of the production and activity of secondary small interfering RNAs in C. elegans. EMBO J. 26, 5007–5019. doi: 10.1038/sj.emboj.7601910
39. Bachman, P. M., Bolognesi, R., Moar, W. J., Mueller, G. M., Paradise, M. S., Ramaseshadri, P., et al. (2013). Characterization of the spectrum of insecticidal activity of a double-stranded RNA with targeted activity against Western Corn Rootworm (Diabrotica virgifera virgifera LeConte). Transgenic Res. 22, 1207 1222. doi: 10.1007/s11248-013-9716-5
40. Baum, J. A., Bogaert, T., Clinton, W., Heck, G. R., Feldmann, P., Ilagan, O., et al. (2007). Control of coleopteran insect pests through RNA interference. Nat. Biotechnol. 25, 1322–1326. doi: 10.1038/nbt1359
41. Bhatia,V.,Bhattacharya,R.,Uniyal,P.L.,Singh,R.,and Niranjan,R.S.(2012).Host Generated siRNAs Attenuate Expression of Serine Protease Gene in Myzus persicae. PloS One 7, e46343–e46343. doi: 10.1371/journal.pone.0046343
42. Billi,A.C.,Fischer,S.E.,andKim, J.K. (2014).EndogenousRNAipathways inC. elegans. WormBook,ed.TheC.elegansResearchCommunity, WormBook1–49. doi: 10.1895/wormbook.1.170.1
43. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell (2009) 136(2):215–33. doi:10.1016/j.cell.2009.01.002

*Corresponding Author: **Muhammad Sufyan**

44. Scaria V, Hariharan M, Maiti S, Pillai B, Brahmachari SK. Host-virus interaction: a new role for microRNAs. Retrovirology (2006) 3:68. doi:10.1186/1742-4690-3-68
45. Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis DA, et al. SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 15(9):1640–51. doi:10.1261/rna.1560209
46. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 10(10):704–14. doi:10.1038/nrg2634
47. Rodriguez LL, Gay CG. Development of vaccines toward the global control and eradication of foot-and mouth disease. Expert Rev Vaccines. 2011;10(3):377–87.
48. Motamedi-Sedeh F, Soleimanjahi H, Jalilian AR, Mahravani H, Shafaee K, Sotoodeh M, et al. Development of protective immunity against inactivated Iranian isolate of foot-and-mouth disease virus type O/IRN/2007 using gamma ray-irradiated vaccine on BALB/c mice and Guinea pigs. Intervirology. 2015;58(3):190–6.
49. Cao Y, Lu Z, Li Y, Sun P, Li D, Li P, et al. Poly(I: C) combined with multi-epitope protein vaccine completely protects against virulent foot-and-mouth disease virus challenge in pigs. Antiviral Res. 2013;97(2):145–53.
50. Guo HC, Sun SQ, Jin Y, Yang SL, Wei YQ, Sun DH, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res. 2013;44(1):1–13.
51. Shao JJ, Wong CK, Lin T, Lee SK, Cong GZ, Sin FWY, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type o in swine. Clin Vaccine Immunol. 2011;18(1):143–9.
52. Zhang Z, Pan L, Ding Y, Zhou P, Lv J, Chen H, et al. Efficacy of synthetic peptide candidate vaccines against serotype-A foot-and-mouth disease virus in cattle. Appl Microbiol Biotechnol. 2015;99(3):1389–98.
53. Young JR, Suon S Andrews CJ, Henry LA and Windsor PA: Assessment of financial impact of foot and mouth disease on smallholder cattle farmers in Southern Cambodia. Transbound Emerg Dis 60:166-174, 2013.
54. Fasina FO, Connell DR, Talabi OA, Lazarus DD, Adeleke GA, Olusanya TP and Hernandez JA: Foot-and-mouth disease virus strains and examination of exposure factors associated with seropositivity of cattle herds in Nigeria during 2007-2009. Prev Vet Med 109: 334-342, 2013.
55. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215 233 DOI 10.1016/j.cell.2009.01.002.
56. Basagoudanavar SH,Ranjitha HB,HosamaniM,KolangathSM,SelvanRPT,Sreeni vasa BP, Saravanan P,Sanyal A,VenkataramananR. 2019. Efficient inhibition of foot-and-mouth disease virus replication in vitro by artificial microRNA targeting 3Dpolymerase. Acta Virologica 63:475 479 DOI 10.4149/av_2019_407.
57. BoudreauRL,MartinsI,DavidsonBL. 2009. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Molecular Therapy 17:169 175 DOI 10.1038/mt.2008.231.
58. Lai, C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J.; Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 2020, 55, 105924. [CrossRef] [PubMed]
59. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [CrossRef] [PubMed]
60. Rambaut, A, Posada, D, Crandall, KA and Holmes, EC (2004). The causes and consequences of HIV evolution. Nat Rev Genet 5: 52–61.
61. Rueckert, R.R. (1996) Picornaviridae: the viruses and their replica tion. In Field's Virology (Fields, B.N. et al., eds), pp. 609–654, Lippincott-Raven, Philadelphia and New York
62. Moraes, M.P. et al. (2002) Early protection against homologous challenge after a single dose of replication-defective human adeno virus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20, 1631–1639
63. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nature Medicine 11,50–55. doi:10.1038/nm1164
64. Brock A, Krause S, Li H, Kowalski M, Goldberg MS, Collins JJ, Ingber DE (2014) Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice. Science Translational Medicine 6, 217ra2. doi:10.1126/scitranslmed.3007048

*Corresponding Author: **Muhammad Sufyan**